These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16413185)

  • 1. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.
    Cavasotto CN; Ortiz MA; Abagyan RA; Piedrafita FJ
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1969-74. PubMed ID: 16413185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
    Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
    San Juan AA
    Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.
    Traxler P; Green J; Mett H; Séquin U; Furet P
    J Med Chem; 1999 Mar; 42(6):1018-26. PubMed ID: 10090785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovering novel 3-nitroquinolines as a new class of anticancer agents.
    Li HH; Huang H; Zhang XH; Luo XM; Lin LP; Jiang HL; Ding J; Chen KX; Liu H
    Acta Pharmacol Sin; 2008 Dec; 29(12):1529-38. PubMed ID: 19026174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiproliferative activity of unsaturated quinoline derivatives.
    Montgomery GJ; McKeown P; McGown AT; Robins DJ
    Anticancer Drug Des; 2000 Jun; 15(3):171-81. PubMed ID: 11049085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
    Abouzid K; Shouman S
    Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH; Song YC; Kim SH; Jo H; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
    Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
    Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
    Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
    J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
    J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
    Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones.
    Xiao ZP; Li HQ; Shi L; Lv PC; Song ZC; Zhu HL
    ChemMedChem; 2008 Jul; 3(7):1077-82. PubMed ID: 18433075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells.
    Ghosh S; Zheng Y; Jun X; Narla RK; Mahajan S; Navara C; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1998 Nov; 4(11):2657-68. PubMed ID: 9829728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
    Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
    Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
    Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
    Li S; Sun X; Zhao H; Tang Y; Lan M
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4004-9. PubMed ID: 22595177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.